Gert van Wyk is ready to take BioCertica to
the world—for the betterment of healthcare
BioCertica is a precision-health company that transforms genetic insights into actionable lifestyle and medical guidance.
The aim of the business is to help individuals and healthcare providers move from reactive treatment to proactive prevention by decoding how someone’s unique DNA interacts with nutrition, exercise, medication, and chronic-disease risk.
Gert van Wyk, Founder and CEO of BioCertica, explains: ”We bridge the gap between cutting-edge genomics and everyday healthcare. Most people either never access their genetic data or receive raw reports with little context. We make this information accessible, clinically relevant, and easy to use so that better health decisions become routine rather than aspirational.”
What sets BioCertica apart is an integrated ecosystem that combines consumer DNA testing, a practitioner portal, and AI-driven analytics.
Their roadmap looks beyond ancestry or simple traits.
“We concentrate on extending health span through evidence-based recommendations and longitudinal tracking. From day one, we have operated with a global regulatory mindset, embedding GDPR, HIPAA, and POPIA compliance into our platform as we expand beyond South Africa,” van Wyk continues.
Milestones and a personal turning point
Since founding the business in 2019 van Wyk has overseen many milestones, with some of the most important being the completion of a pilot study in Turkey and actively building to expand into the UAE and Europe with a strong logistics base in the Netherlands.
Each step in the process, he says, has validated their technology and business model while proving that the business’ vision resonates across different markets.
”We would like to take BioCertica public and acquire companies that we believe will aid our expansion vision. Building a practitioner network and launching full-funnel digital marketing that consistently drives double-digit monthly user growth is also an important step we must take,” van Wyk says.
But not all has been smooth sailing.
The scariest moment for van Wyk came early in the pandemic when a critical equipment dispute threatened to derail BioCertica’s genotyping operations.
Supply-chain delays and unexpected costs forced the business to choose between slowing down or innovating fast.
“We opted to fight for fair terms, renegotiate, and streamline our processes. That experience hardened our operational discipline and reinforced the importance of resilience—lessons we still draw on,” he explains.
Leadership and bold goals
Van Wyk is a believer in leadership that is based on clarity of vision and empowerment.
“I set ambitious, measurable goals and then trust the team to own their execution. My style is collaborative and transparent: everyone understands both the ‘why’ and the ‘how’, and ideas can surface from any level. I also subscribe to servant leadership—removing obstacles so that talented people can do their best work,” he states.
Looking ahead, van Wyk aims to turn BioCertica into a global longevity platform.
Over the next five years, the plan is to scale across the USA and Europe, expand into AI-driven preventive care, and integrate real-world assets such as wearable data and secure digital IDs.
“The ultimate goal is to empower millions to add quality years to their lives while positioning BioCertica as the trusted bridge between genomics, everyday health, and the next wave of personalised medicine,” van Wyk concludes.
